| Assessment Status | Full Assessment Complete |
| HTA ID | - |
| Drug | Fingolimod |
| Brand | Gilenya® |
| Indication | For the treatment of highly active relapsing-remitting multiple sclerosis. |
| Assessment Process | |
| Rapid review commissioned | 03/12/2010 |
| Rapid review completed | 03/01/2011 |
| Rapid review outcome | Full Pharmaconomic Evaluation Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 03/06/2011 |
| NCPE assessment completed | 20/09/2011 |
| NCPE assessment outcome | Reimbursement not recommended at the submitted price. |
22nd September 2011
Following a price revision we now consider Fingolimod (Gilenya®) a cost-effective therapy for the treatment of relapsing-remitting multiple sclerosis patients in the Irish healthcare setting.